<?xml version="1.0"?><!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.0//EN" "http://www.ncbi.nlm.nih.gov:80/entrez/query/static/PubMed.dtd"><ArticleSet>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>SPIM 2014</ArticleTitle>
		<FirstPage>3</FirstPage>
		<LastPage>3</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Dr Jean-Yves</FirstName>
				<LastName>Berthon</LastName>
				<Affiliation>CEO, Greentech SA</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList>
			<ArticleId IdType="pii">ejd.2015.2580</ArticleId>
			<ArticleId IdType="doi">10.1684/ejd.2015.2580</ArticleId>
		</ArticleIdList>
		<History></History>
		<Abstract></Abstract>
	</Article>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Nuclear receptor peroxisome proliferator activated receptor (PPAR) &#x003B2;/&#x003B4; in skin wound healing and cancer</ArticleTitle>
		<FirstPage>4</FirstPage>
		<LastPage>11</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Alexandra</FirstName>
				<LastName>Montagner</LastName>
				<Affiliation>INRA ToxAlim Integrative Toxicology and Metabolism UMR1331, Chemin de Tournefeuille, Toulouse Cedex, France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Walter</FirstName>
				<LastName>Wahli</LastName>
				<Affiliation>INRA ToxAlim Integrative Toxicology and Metabolism UMR1331, Chemin de Tournefeuille, Toulouse Cedex, France, Center for Integrative Genomics, University of Lausanne, Le G&#x000E9;nopode, Lausanne, Switzerland, Lee Kong Chian School of Medicine, Nanyang Technological University, Academia, College Road, Singapore, Singapore</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Nguan Soon</FirstName>
				<LastName>Tan</LastName>
				<Affiliation>School of Biological Sciences, Nanyang Technological University, Nanyang Drive, Singapore, Singapore, Institute of Molecular and Cell Biology, Proteos, A*STAR, Singapore, Singapore</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList>
			<ArticleId IdType="pii">ejd.2014.2505</ArticleId>
			<ArticleId IdType="doi">10.1684/ejd.2014.2505</ArticleId>
		</ArticleIdList>
		<History></History>
		<Abstract>We review the functions of peroxisome proliferator activated receptor (PPAR) &#x003B2;/&#x003B4; in skin wound healing and cancer. In particular, we highlight the roles of PPAR&#x003B2;/&#x003B4; in inhibiting keratinocyte apoptosis at wound edges via activation of the PI3K/PKB&#x003B1;/Akt1 pathway and its role during re-epithelialization in regulating keratinocyte adhesion and migration. In fibroblasts, PPAR&#x003B2;/&#x003B4; controls IL-1 signalling and thereby contributes to the homeostatic control of keratinocyte proliferation. We discuss its therapeutic potential for treating diabetic wounds and inflammatory skin diseases such as psoriasis and acne vulgaris. PPAR&#x003B2;/&#x003B4; is classified as a tumour growth modifier; it is activated by chronic low-grade inflammation, which promotes the production of lipids that, in turn, enhance PPAR&#x003B2;/&#x003B4; transcription activity. Our earlier work unveiled a cascade of events triggered by PPAR&#x003B2;/&#x003B4; that involve the oncogene Src, which promotes ultraviolet-induced skin cancer in mice via enhanced EGFR/Erk1/2 signalling and the expression of epithelial-to-mesenchymal transition (EMT) markers. Interestingly, PPAR&#x003B2;/&#x003B4; expression is correlated with the expression of SRC and EMT markers in human skin squamous cell carcinoma. Furthermore, there is a positive interaction between PPAR&#x003B2;/&#x003B4;, SRC, and TGF&#x003B2;1 at the transcriptional level in various human epithelial cancers. Taken together, these observations suggest the need for evaluating PPAR&#x003B2;/&#x003B4; modulators that attenuate or increase its activity, depending on the therapeutic target.</Abstract>
		<ObjectList>
			<Object Type="keyword">
				<Param Name="value">diabetic wound</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">epithelial tumours</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">keratinocytes</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">non-melanoma skin cancer</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">nuclear receptors</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">wound healing</Param>
			</Object>
		</ObjectList>
	</Article>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<ArticleTitle>Pluripotent stem cells as a cellular model for skin: relevance for physiopathology, cell/gene therapy and drug screening</ArticleTitle>
		<FirstPage>12</FirstPage>
		<LastPage>17</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Ayelet</FirstName>
				<LastName>Levy</LastName>
				<Affiliation>Inserm U976,&#x0000A;Universit&#x000E9; Paris-Diderot,&#x0000A;H&#x000F4;pital St-Louis,&#x0000A;1, Av. Vellefaux 75010 Paris,&#x0000A;France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Isabelle</FirstName>
				<LastName>Petit</LastName>
				<Affiliation>Inserm U976,&#x0000A;Universit&#x000E9; Paris-Diderot,&#x0000A;H&#x000F4;pital St-Louis,&#x0000A;1, Av. Vellefaux 75010 Paris,&#x0000A;France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Daniel</FirstName>
				<LastName>Aberdam</LastName>
				<Affiliation>Inserm U976,&#x0000A;Universit&#x000E9; Paris-Diderot,&#x0000A;H&#x000F4;pital St-Louis,&#x0000A;1, Av. Vellefaux 75010 Paris,&#x0000A;France</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList>
			<ArticleId IdType="pii">ejd.2015.2537</ArticleId>
			<ArticleId IdType="doi">10.1684/ejd.2015.2537</ArticleId>
		</ArticleIdList>
		<History></History>
		<Abstract>The skin represents the largest tissue in the human body. Its external part, the epidermis, accomplishes vital functions such as barrier protection, thermoregulation and immune function. The mammalian skin epidermis has been for decades the paradigm for studying the molecular events that occur in tissue homeostasis and repair. Many genes and signaling pathways have been identified by the use of manipulated transgenic and KO mice. However, despite numerous elegant transgenic mice experiments, absence of an appropriate in vitro model system has hampered the molecular study of the early events responsible for epidermal and dermal commitments, stages at which congenital genetic alterations are responsible for hundreds of rare skin diseases. For most of them, etiology and treatment are still missing. Here we review the last decade of studies aimed at designing cellular models from pluripotent stem cells (PSC) that recapitulate in vitro the main molecular steps of skin formation. As described below, PSC-based models are powerful tools to (i) clarify early molecular events that occur during epithelial/mesenchymal interactions, (ii) produce in large amount skin cells that could become an alternative for cell/gene therapies and (iii) screen for therapeutic compounds to treat genodermatoses.</Abstract>
		<ObjectList>
			<Object Type="keyword">
				<Param Name="value">pluripotent stem cells</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">drug screening</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">genodermatoses</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">skin diseases</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">epidermolysis bullosa</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">ectodermal dysplasia syndromes</Param>
			</Object>
		</ObjectList>
	</Article>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<Replaces IdType="pubmed">26083670</Replaces>
		<ArticleTitle>Skin and arthropods: an effective interaction used by pathogens in vector-borne diseases</ArticleTitle>
		<FirstPage>18</FirstPage>
		<LastPage>22</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Quentin</FirstName>
				<LastName>Bernard</LastName>
				<Affiliation>EA7290&#x000A0;: Virulence bact&#x000E9;rienne pr&#x000E9;coce&#x000A0;:&#x0000A;groupe borr&#x000E9;liose de Lyme,&#x0000A;universit&#x000E9; de Strasbourg, France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Beno&#x000EE;t</FirstName>
				<LastName>Jaulhac</LastName>
				<Affiliation>EA7290&#x000A0;: Virulence bact&#x000E9;rienne pr&#x000E9;coce&#x000A0;:&#x0000A;groupe borr&#x000E9;liose de Lyme,&#x0000A;universit&#x000E9; de Strasbourg, France, Centre national de r&#x000E9;f&#x000E9;rence Borrelia,&#x0000A;centre hospitalier Universitaire,&#x0000A;Strasbourg, France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Nathalie</FirstName>
				<LastName>Boulanger</LastName>
				<Affiliation>EA7290&#x000A0;: Virulence bact&#x000E9;rienne pr&#x000E9;coce&#x000A0;:&#x0000A;groupe borr&#x000E9;liose de Lyme,&#x0000A;universit&#x000E9; de Strasbourg, France, Centre national de r&#x000E9;f&#x000E9;rence Borrelia,&#x0000A;centre hospitalier Universitaire,&#x0000A;Strasbourg, France</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList><ArticleId IdType="pii">ejd.2015.2550</ArticleId><ArticleId IdType="doi">10.1684/ejd.2015.2550</ArticleId></ArticleIdList>
		<History></History>
		<Abstract>In the last years, the skin has been described as a major interface in arthropod borne diseases. Although it constitutes an efficient immune and physical barrier, pathogens have developed effective strategies to thwart the host. In this process, the arthropod plays a major role. For mosquitoes, the quick blood meal is made through an efficient inoculation process directly into the blood vessel. For the long lasting blood meal of hard ticks, the sophisticated biting pieces and the tick saliva provide potent tools to help pathogen transmission. Lyme borreliosis and leishmaniases have been particularly well investigated in this context.</Abstract>
		<ObjectList>
			<Object Type="keyword">
				<Param Name="value">keratinocytes</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">fibroblasts</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">dendritic cell</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">arthropod saliva</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">vector-borne diseases</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">leishmaniasis</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">Lyme borreliosis</Param>
			</Object>
		</ObjectList>
	</Article>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<Replaces IdType="pubmed">26083671</Replaces>
		<ArticleTitle>New easy handling and sampling device for bioavailability screening of topical formulations</ArticleTitle>
		<FirstPage>23</FirstPage>
		<LastPage>29</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Damien</FirstName>
				<LastName>Salmon</LastName>
				<Affiliation>EA 4169&#x000A0;: Aspect fondamentaux,&#x0000A;cliniques et th&#x000E9;rapeutiques de la fonction barri&#x000E8;re cutan&#x000E9;e,&#x0000A;Laboratoire de Pharmacie Gal&#x000E9;nique Industrielle,&#x0000A;Plateforme FRIPHARM, Facult&#x000E9; de Pharmacie,&#x0000A; SFR Lyon-Est Sant&#x000E9;, Universit&#x000E9; Claude Bernard Lyon 1.&#x0000A;8, avenue Rockefeller; 69373 Lyon cedex 08,&#x0000A;France&#x0000A;www.fripharm.com, Unit&#x000E9; de pr&#x000E9;paration et contr&#x000F4;le des m&#x000E9;dicaments,&#x0000A;Service Pharmaceutique,&#x0000A;Plateforme FRIPHARM,&#x0000A;Groupement Hospitalier Edouard Herriot,&#x0000A;Hospices Civils de Lyon.&#x0000A;5, Place d&#x02019;Arsonval&#x000A0;; 69437 Lyon cedex 03,&#x0000A;France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Elodie</FirstName>
				<LastName>Gilbert</LastName>
				<Affiliation>EA 4169&#x000A0;: Aspect fondamentaux,&#x0000A;cliniques et th&#x000E9;rapeutiques de la fonction barri&#x000E8;re cutan&#x000E9;e,&#x0000A;Laboratoire de Pharmacie Gal&#x000E9;nique Industrielle,&#x0000A;Plateforme FRIPHARM, Facult&#x000E9; de Pharmacie,&#x0000A; SFR Lyon-Est Sant&#x000E9;, Universit&#x000E9; Claude Bernard Lyon 1.&#x0000A;8, avenue Rockefeller; 69373 Lyon cedex 08,&#x0000A;France&#x0000A;www.fripharm.com</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Bruna</FirstName>
				<LastName>Gioia</LastName>
				<Affiliation>Unit&#x000E9; de pr&#x000E9;paration et contr&#x000F4;le des m&#x000E9;dicaments,&#x0000A;Service Pharmaceutique,&#x0000A;Plateforme FRIPHARM,&#x0000A;Groupement Hospitalier Edouard Herriot,&#x0000A;Hospices Civils de Lyon.&#x0000A;5, Place d&#x02019;Arsonval&#x000A0;; 69437 Lyon cedex 03,&#x0000A;France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Marek</FirstName>
				<LastName>Haftek</LastName>
				<Affiliation>EA 4169&#x000A0;: Aspect fondamentaux,&#x0000A;cliniques et th&#x000E9;rapeutiques de la fonction barri&#x000E8;re cutan&#x000E9;e,&#x0000A;Laboratoire de Pharmacie Gal&#x000E9;nique Industrielle,&#x0000A;Plateforme FRIPHARM, Facult&#x000E9; de Pharmacie,&#x0000A; SFR Lyon-Est Sant&#x000E9;, Universit&#x000E9; Claude Bernard Lyon 1.&#x0000A;8, avenue Rockefeller; 69373 Lyon cedex 08,&#x0000A;France&#x0000A;www.fripharm.com</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Christine</FirstName>
				<LastName>Pivot</LastName>
				<Affiliation>Unit&#x000E9; de pr&#x000E9;paration et contr&#x000F4;le des m&#x000E9;dicaments,&#x0000A;Service Pharmaceutique,&#x0000A;Plateforme FRIPHARM,&#x0000A;Groupement Hospitalier Edouard Herriot,&#x0000A;Hospices Civils de Lyon.&#x0000A;5, Place d&#x02019;Arsonval&#x000A0;; 69437 Lyon cedex 03,&#x0000A;France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Bernard</FirstName>
				<LastName>Verrier</LastName>
				<Affiliation>UMR 5305&#x000A0;:&#x0000A;Laboratoire de Biologie Tissulaire et d&#x02019;Ing&#x000E9;nierie Th&#x000E9;rapeutique,&#x0000A;CNRS/Universit&#x000E9; Claude Bernard Lyon 1,&#x0000A;Institut de Biologie et Chimie des Prot&#x000E9;ines.&#x0000A;7, Passage du Vercors&#x000A0;; 69367 Lyon Cedex 07,&#x0000A;France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Fabrice</FirstName>
				<LastName>Pirot</LastName>
				<Affiliation>EA 4169&#x000A0;: Aspect fondamentaux,&#x0000A;cliniques et th&#x000E9;rapeutiques de la fonction barri&#x000E8;re cutan&#x000E9;e,&#x0000A;Laboratoire de Pharmacie Gal&#x000E9;nique Industrielle,&#x0000A;Plateforme FRIPHARM, Facult&#x000E9; de Pharmacie,&#x0000A; SFR Lyon-Est Sant&#x000E9;, Universit&#x000E9; Claude Bernard Lyon 1.&#x0000A;8, avenue Rockefeller; 69373 Lyon cedex 08,&#x0000A;France&#x0000A;www.fripharm.com, Unit&#x000E9; de pr&#x000E9;paration et contr&#x000F4;le des m&#x000E9;dicaments,&#x0000A;Service Pharmaceutique,&#x0000A;Plateforme FRIPHARM,&#x0000A;Groupement Hospitalier Edouard Herriot,&#x0000A;Hospices Civils de Lyon.&#x0000A;5, Place d&#x02019;Arsonval&#x000A0;; 69437 Lyon cedex 03,&#x0000A;France</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList><ArticleId IdType="pii">ejd.2015.2551</ArticleId><ArticleId IdType="doi">10.1684/ejd.2015.2551</ArticleId></ArticleIdList>
		<History></History>
		<Abstract>Biopharmaceutical assessment of topical drug formulations is widely carried out by using vertical diffusion cells (Franz type cell). Although Franz diffusion cell model is well designed for percutaneous absorption studies, the extent of drug penetration within the skin requires more adapted device. Recently, we have developed a new patented versatile, easy-to-use, and disposable diffusion cell called VitroPharma. In this study we have assessed the cutaneous bioavailability of caffeine as hydrophilic compound model using Franz diffusion cell and VitroPharma. The percutaneous absorption of caffeine assessed with Franz diffusion cell and VitroPharma was characterized by using (i) finite dose model and (ii) classical pharmacokinetic analysis. Furthermore, the follow-up of caffeine penetration within the skin was determined by sequential measurements of tissular drug concentration throughout the time of skin exposure with VitroPharma. However, classical experimental design using Franz diffusion cell involved unique determination of tissular concentration at the final point of skin exposure protocol. Finally, device equivalence between Franz diffusion cell and VitroPharma was claimed from percutaneous absorption data analysis. Concomitant assessment of dual penetration and permeation kinetics by using VitroPharma reinforced the understanding of skin drug delivery.</Abstract>
		<ObjectList>
			<Object Type="keyword">
				<Param Name="value">caffeine</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">Franz diffusion cell</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">permeability assay</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">porcine skin</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">VitroPharma</Param>
			</Object>
		</ObjectList>
	</Article>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<Replaces IdType="pubmed">26083672</Replaces>
		<ArticleTitle>Update on the pathogenesis of squamous cell carcinoma development in recessive dystrophic epidermolysis bullosa</ArticleTitle>
		<FirstPage>30</FirstPage>
		<LastPage>32</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Minhee</FirstName>
				<LastName>Kim</LastName>
				<Affiliation>Department of Dermatology,&#x0000A;St. George Hospital,&#x0000A;Sydney, Australia;, Dept of Medicine,&#x0000A;Queen Elizabeth Hospital,&#x0000A;Adelaide, SA</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Dedee F</FirstName>
				<LastName>Murrell</LastName>
				<Affiliation>Department of Dermatology,&#x0000A;St. George Hospital,&#x0000A;Sydney, Australia;, The University of New South Wales,&#x0000A;Sydney, Australia</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList><ArticleId IdType="pii">ejd.2015.2552</ArticleId><ArticleId IdType="doi">10.1684/ejd.2015.2552</ArticleId></ArticleIdList>
		<History></History>
		<Abstract>Recessive dystrophic epidermolysis bullosa (RDEB) is a recessively inherited blistering disorder due to mutations in the collagen VII gene, COL7A1. Patients with RDEB have up to a 50 fold increased incidence of cutaneous squamous cell carcinoma (cSCC) which is independent of ultraviolet (UV) exposure. The pathogenesis of cSCC development and its aggressive nature in RDEB remain unclear. To date there is no convincing evidence that RDEB SCC and UV SCC are distinct. A recent discovery of a remarkably distinct tumour microenvironment in part explains the aggressive nature of RDEB SCC and the importance of collagen VII expression as a potential therapeutic measure. The role of gram negative flagellate bacteria increasing the risk of SCC development in chronic wounds has recently been elucidated in RDEB.</Abstract>
		<ObjectList>
			<Object Type="keyword">
				<Param Name="value">Collagen VII</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">high mortality</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">pathogenesis</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">RDEB</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">SCC</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">tumour microenvironment</Param>
			</Object>
		</ObjectList>
	</Article>
	<Article>
		<Journal>
			<PublisherName>John Libbey Eurotext</PublisherName>
			<JournalTitle>Eur J Dermatol</JournalTitle>
			<Issn>1167-1122</Issn>
			<Volume>25</Volume>
			<Issue>S1</Issue>
			<PubDate PubStatus="ppublish">
				<Year>2015</Year>
				<Month>04</Month>
				<Day>01</Day>
			</PubDate>
		</Journal>
		<Replaces IdType="pubmed">26083673</Replaces>
		<ArticleTitle>How do epidermal matrix metalloproteinases support re-epithelialization during skin healing?</ArticleTitle>
		<FirstPage>33</FirstPage>
		<LastPage>42</LastPage>
		<AuthorList>
			<Author>
				<FirstName EmptyYN="N">Anna</FirstName>
				<LastName>Michopoulou</LastName>
				<Affiliation>Laboratoire de biologie tissulaire et d&#x02019;ing&#x000E9;nierie th&#x000E9;rapeutique,&#x0000A;Institut de Biologie et Chimie des Prot&#x000E9;ines,&#x0000A;UMR 5305, CNRS; Universit&#x000E9; Lyon 1,&#x0000A;7 passage du Vercors, 69367, Lyon, France</Affiliation>
			</Author>
			<Author>
				<FirstName EmptyYN="N">Patricia</FirstName>
				<LastName>Rousselle</LastName>
				<Affiliation>Laboratoire de biologie tissulaire et d&#x02019;ing&#x000E9;nierie th&#x000E9;rapeutique,&#x0000A;Institut de Biologie et Chimie des Prot&#x000E9;ines,&#x0000A;UMR 5305, CNRS; Universit&#x000E9; Lyon 1,&#x0000A;7 passage du Vercors, 69367, Lyon, France</Affiliation>
			</Author>
		</AuthorList>
		<PublicationType></PublicationType>
		<ArticleIdList><ArticleId IdType="pii">ejd.2015.2553</ArticleId><ArticleId IdType="doi">10.1684/ejd.2015.2553</ArticleId></ArticleIdList>
		<History></History>
		<Abstract>Epithelialization of normal wounds occurs by an orderly series of events whereby keratinocytes migrate, proliferate, and differentiate to restore the epidermal barrier function. Keratinocyte migration is one of the earliest and crucial events determining the efficiency of the overall wound repair process. In response to various stimuli including that of growth factors, cytokines and the extracellular matrix, activated keratinocytes at the edges of the wound undergo dramatic morphological changes according to their migratory behaviour through development of protrusive adhesion contacts and cytoskeleton rearrangements. These phenotypic changes are accompanied by the upregulated expression of a new set of genes, among which are adhesion receptors and specific matrix degrading enzymes named matrix metalloproteinases (MMPs). The tightly regulated spatial and temporal MMP expression is crucial for proper re-epithelialization. These multi-domain zinc-containing endopeptidases are necessary for the proper completion of multiple features of epidermal regeneration. They play a key role in the migration process by controlling the repeated cycles of keratinocyte attachment and retraction. In the meantime, they process, degrade or remodel the extracellular matrix often producing cleavages in a gain-of-function manner.</Abstract>
		<ObjectList>
			<Object Type="keyword">
				<Param Name="value">extracellular matrix</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">matrix metalloproteinases</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">keratinocyte</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">migration</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">skin</Param>
			</Object>
			<Object Type="keyword">
				<Param Name="value">wound healing</Param>
			</Object>
		</ObjectList>
	</Article>

</ArticleSet>